Stay updated with breaking news from Piotr Trzonkowski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New biomarker may facilitate monitoring T1D patients’ healthIncrease in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies...
Gdańsk, Poland – 11 March 2024 – PolTREG S.A. , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has received CGMP...
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell...
30.01.2024 - Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announced that Prof. Piotr Trzonkowski, CEO, ... Seite 1
Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. , a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide range of...